Skip to content
    CaaS Capital logo

    CaaS Capital

    New York, New York, United StatesFounded 2019

    CaaS Capital is a Series B to Series C stage investment firm based in New York, New York, United States. It has made 6 investments, with focus areas including Biotech & Life Sciences. 100% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-c (67% of deals). Average disclosed round size is $105.2M (across 6 rounds with reported amounts).

    Find people at CaaS Capital on Goldilocks AI

    Portfolio

    6

    Fund Size

    $971.0M

    Top Stage

    Series C

    Last 12 Mo

    0

    Team

    DH

    Dr. Hua Yi

    Managing Director

    SQ

    Saif Qazi

    Vice President

    Portfolio Breakdown

    Stage Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    6 investments
    CompanyRoundAmountDate
    Umoja Biopharma logoUmoja BiopharmaSeries C$100MJan 2025
    HotSpot Therapeutics, Inc. logoHotSpot Therapeutics, Inc.Series C$100MNov 2021
    Artios Pharma Limited logoArtios Pharma LimitedSeries C$153MJul 2021
    StrideBio, Inc. logoStrideBio, Inc.Series B$81.5MMar 2021
    Amunix Pharmaceuticals, Inc. logoAmunix Pharmaceuticals, Inc.Series B$117MMar 2021
    Cyteir Therapeutics logoCyteir TherapeuticsSeries C$80MFeb 2021

    Top Co-Investors

    Janus Henderson Investors2 shared
    Venrock2 shared
    Omega Funds2 shared
    LSP2 shared
    Sofinnova Partners2 shared
    Ally Bridge Group1 shared
    Novo Holdings1 shared
    Lightstone Ventures1 shared
    Osage University Partners1 shared
    Bain Capital Life Sciences1 shared
    BlackRock1 shared
    ArrowMark Partners1 shared

    Last updated: 8 March 2026